Molecular Mechanisms and Emerging Therapeutics in Multiple Myeloma
A special issue of Hemato (ISSN 2673-6357).
Deadline for manuscript submissions: 31 January 2026 | Viewed by 39
Special Issue Editors
Interests: immunology; genetics; myeloproliferative neoplasms; leukemia; lymphoma
Interests: multiple myeloma; drug resistance; CAR-T; molecular pathway; stem cell; radiation protection; chemo protection; novel target
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Multiple myeloma (MM) remains an incurable hematologic malignancy despite significant advances in treatment modalities over recent decades. The rapid development of next-generation sequencing, single-cell transcriptomics, and proteomic profiling has unraveled the complex molecular landscape of MM, including clonal evolution, genetic heterogeneity, and resistance mechanisms. Concurrently, novel therapeutic strategies—such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, bispecific T-cell engagers, CAR-T cells, and agents targeting apoptosis, ferroptosis, and the bone marrow microenvironment—are reshaping the treatment paradigm. This Special Issue aims to highlight recent breakthroughs in the understanding of MM biology and explore how these findings translate into innovative and more-effective therapeutic approaches. We welcome original research, reviews, and perspectives covering topics such as drug resistance, immune evasion, microenvironmental interactions, and biomarker discovery, as well as preclinical and clinical evaluations of emerging therapies. Our goal is to provide a comprehensive update on the current challenges and future directions in MM research and management.
Dr. Velizar Shivarov
Guest Editor
Dr. Jian Wu
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Hemato is an international peer-reviewed open access quarterly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- multiple myeloma
- myeloma
- drug resistance
- stem cell
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
